Fig. 7
The Utility of GloMICS in Predicting Immunotherapy Responses in MUC Patients. (A) Differences in restricted mean survival time (RMS) at 6 months and 1 year after treatment between high and low GloMICS groups. (B) Differences in long-term survival (LTS) 3 months post-treatment between high and low GloMICS groups. (C) Distribution of GloMICS across different immunotherapy response categories. (D) Variations in activation levels at each step of the TIP between high and low GloMICS groups. (E) TIDE-based prediction of immunotherapy response. (F) TIDE algorithm predictions of TIDE scores between low and high GloMICS groups. (F) TIDE algorithm predicts CD8 T-cell levels in high and low GloMICS groups. (G) Survival analysis in the GSE78220 dataset comparing high and low GloMICS groups. (H) Survival analysis in the GSE135222 dataset comparing high and low GloMICS groups. (I) Distribution of GloMICS across different immunotherapy response categories in the GSE91061 dataset.
